GSK Drug For Further Processing
NDC Database

GSK Drug For Further Processing

NDC Database

National Drug Code (NDC) records including drug products, NDC numbers, nonproprietary names, dosage forms, strengths, labelers and marketing information.

Drug for Further Processing
  • Total Records 13
  • Latest Marketing Date 2022-01-01
  • Data Source FDA
  • First Marketing Date 2013-06-17
All
20
View
Bulk Ingredient
7
View
Drug for Further Processing
13
View
Company Overview

Company

GSK Drug For Further Processing

Country

United Kingdom

Website

Visit Website

Email

Social Profiles

Company Snapshot

GSK Drug For Further Processing

980 Great West Road, Brentford, Middlesex TW8 9GS England

United Kingdom

www.gsk.com:443/en-gb/ View on Map
NDC Records ( 13 records )
2020
01 Jan
Drug for Further Processing NDC: 58437-016

Nonproprietary Name

sumatriptan

Dosage Form

TABLET, FILM COATED

Strength

25 mg/1

Labeler

GlaxoSmithKline LLC

Marketing Category

DRUG FOR FURTHER PROCESSING

58437-016

Substance

SUMATRIPTAN SUCCINATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2020-01-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2020
01 Jan
Drug for Further Processing NDC: 58437-017

Nonproprietary Name

sumatriptan

Dosage Form

TABLET, FILM COATED

Strength

25 mg/1

Labeler

GlaxoSmithKline LLC

Marketing Category

DRUG FOR FURTHER PROCESSING

58437-017

Substance

SUMATRIPTAN SUCCINATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2020-01-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2020
01 Jan
Drug for Further Processing NDC: 58437-018

Nonproprietary Name

sumatriptan

Dosage Form

TABLET, FILM COATED

Strength

25 mg/1

Labeler

GlaxoSmithKline LLC

Marketing Category

DRUG FOR FURTHER PROCESSING

58437-018

Substance

SUMATRIPTAN SUCCINATE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2020-01-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2020
01 Jan
Drug for Further Processing NDC: 58437-019

Nonproprietary Name

lamotrigine

Dosage Form

TABLET, FILM COATED, EXTENDED RELEASE

Strength

25 mg/1

Labeler

GlaxoSmithKline LLC

Marketing Category

DRUG FOR FURTHER PROCESSING

58437-019

Substance

LAMOTRIGINE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2020-01-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2020
01 Jan
Drug for Further Processing NDC: 58437-020

Nonproprietary Name

lamotrigine

Dosage Form

TABLET, FILM COATED, EXTENDED RELEASE

Strength

50 mg/1

Labeler

GlaxoSmithKline LLC

Marketing Category

DRUG FOR FURTHER PROCESSING

58437-020

Substance

LAMOTRIGINE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2020-01-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2020
01 Jan
Drug for Further Processing NDC: 58437-021

Nonproprietary Name

lamotrigine

Dosage Form

TABLET, FILM COATED, EXTENDED RELEASE

Strength

100 mg/1

Labeler

GlaxoSmithKline LLC

Marketing Category

DRUG FOR FURTHER PROCESSING

58437-021

Substance

LAMOTRIGINE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2020-01-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2020
01 Jan
Drug for Further Processing NDC: 58437-022

Nonproprietary Name

lamotrigine

Dosage Form

TABLET, FILM COATED, EXTENDED RELEASE

Strength

200 mg/1

Labeler

GlaxoSmithKline LLC

Marketing Category

DRUG FOR FURTHER PROCESSING

58437-022

Substance

LAMOTRIGINE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2020-01-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2020
01 Jan
Drug for Further Processing NDC: 58437-023

Nonproprietary Name

lamotrigine

Dosage Form

TABLET

Strength

25 mg/1

Labeler

GlaxoSmithKline LLC

Marketing Category

DRUG FOR FURTHER PROCESSING

58437-023

Substance

LAMOTRIGINE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2020-01-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2020
01 Jan
Drug for Further Processing NDC: 58437-024

Nonproprietary Name

lamotrigine

Dosage Form

TABLET

Strength

100 mg/1

Labeler

GlaxoSmithKline LLC

Marketing Category

DRUG FOR FURTHER PROCESSING

58437-024

Substance

LAMOTRIGINE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2020-01-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2022
01 Jan
Drug for Further Processing NDC: 58437-027

Nonproprietary Name

Dolutegravir and Lamivudine

Dosage Form

TABLET, FILM COATED

Strength

50; 300 mg/1; mg/1

Labeler

GlaxoSmithKline LLC

Marketing Category

DRUG FOR FURTHER PROCESSING

58437-027

Substance

DOLUTEGRAVIR SODIUM; LAMIVUDINE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2022-01-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2015
01 Jan
Drug for Further Processing NDC: 12064-019

Nonproprietary Name

doxorubicin hydrochloride

Dosage Form

INJECTION, SUSPENSION, LIPOSOMAL

Strength

2 mg/mL

Labeler

GlaxoSmithKline Manufacturing SpA

Marketing Category

DRUG FOR FURTHER PROCESSING

12064-019

Substance

DOXORUBICIN HYDROCHLORIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2015-01-01

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2013
17 Jun
Drug for Further Processing NDC: 12064-021

Nonproprietary Name

trametinib

Dosage Form

TABLET, FILM COATED

Strength

0.5 mg/1

Labeler

GlaxoSmithKline Manufacturing SpA

Marketing Category

DRUG FOR FURTHER PROCESSING

12064-021

Substance

TRAMETINIB DIMETHYL SULFOXIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2013-06-17

End Marketing Date

-

Listing Record Certified Through

2026-12-31

2013
17 Jun
Drug for Further Processing NDC: 12064-022

Nonproprietary Name

trametinib

Dosage Form

TABLET, FILM COATED

Strength

2 mg/1

Labeler

GlaxoSmithKline Manufacturing SpA

Marketing Category

DRUG FOR FURTHER PROCESSING

12064-022

Substance

TRAMETINIB DIMETHYL SULFOXIDE

Product Type

DRUG FOR FURTHER PROCESSING

DEA Schedule

Start Marketing Date

2013-06-17

End Marketing Date

-

Listing Record Certified Through

2026-12-31

Related Databases
  • FDA Inspections
    24 View
  • EDQM CEP
    23 View
  • KDMF
    0 View
  • Japan DMF
    0 View
  • Eudra GMP
    0 View
  • NDC Database
    20 View
  • FDA Approved Drugs Database
    377 View
  • Drug Prices in Switzerland
    0 View
NDC Type Breakdown
13 total
  • Drug for Further Processing
Official Source

NDC data is based on publicly available National Drug Code information from the U.S. Food and Drug Administration (FDA).

Visit FDA NDC Directory
NDC Record Details Preview

Explore important National Drug Code information available in the records above.

NDC

58437-016

Nonproprietary Name

sumatriptan

Labeler

GlaxoSmithKline LLC

Dosage Form

TABLET, FILM COATED

FDA NDC Data

National Drug Code information

Regular Updates

Data maintained from official sources

Structured Database

Searchable pharmaceutical data

Reliable Data

Organized NDC records

NDC data is based on publicly available U.S. Food and Drug Administration (FDA) National Drug Code information.

Create a New Buying Request

Fields marked with * are mandatory.

Please enter quantity.
Please select a unit.
Please select quality standard.
Please select request type.
Please provide product specifications.
Please enter additional details.
Please select shipping preference.
Notice: By submitting this buying request, the provided product details and requirements may be published publicly on our marketplace.
Login to Submit